they're cleverly citing tenents of both overall survival and median overall survival to bolster their position when bavi has clearly blown soc mos out of the water in an unprecedented manner : )
If all continues on the current path I would not be surprised if the fda awards aa but with a concurrent p3 on ethical grounds.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.